AI powered Tissue damage Imaging platform, TechsoMed secured $7 Million funding

TechsoMed, AI and Algorithm-powered real-time tissue damage imaging technology provider has now secured $7 million in a Series B equity funding round.

TechsoMed is founded by the Yossi Abu. It is a medical imaging software company developing the BioTrace platform, which is an AI-based technology that enables physicians to detect and visualize tissue viability using standard commercial ultrasound imaging for thermal ablation procedures.

Fred Shane, Managing Partner at Axil Capital, said, "Participation by high-quality investors in this round evidences strong support in TechsoMed's ability to transform thermal ablation treatment and to position itself as a compelling player in the medical imaging and predictive algorithm space. By allowing physicians to provide their patients with a new level of treatment precision, BioTrace has the power to advance thermal ablation therapy to become a first line treatment".

Yossi Abu, CEO, TechsoMed, said, "We are very grateful to both our new and existing investors for sharing our vision and recognizing the valuable impact that our technology brings. Coming from diverse regional markets such as the U.S., Japan, China and the EU, our investors act as driving force towards achieving our goals for scaling our technology and company. With our BioTrace solution and advanced algorithm and image processing technologies, physicians will be able to see more in real time. We hope to eliminate the guess work in ablation therapy."

The Axil Capital led the latest funding round. Other participating investors include the Magna Capital Partners, Yongjin Capital, Radianx Capital, and Cobro Ventures, along with the NextLeap Ventures, and JJDC inc.

The latest funding helps TechsoMed to establish itself as a leading player in the medical imaging and predictive algorithm space, notes the announcement.